Get the Stockscreener App
6.81
2.10%
0.14
After Hours:
6.80
-0.010
-0.15%
Lifecore Biomedical Inc stock is traded at $6.81, with a volume of 231.29K.
It is up +2.10% in the last 24 hours and down -1.23% over the past month.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers differentiated capabilities in the development, filling, and finishing of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid. Lifecore recognizes revenue in two different product categories, CDMO and fermentation.
See More
Previous Close:
$6.67
Open:
$6.82
24h Volume:
231.29K
Relative Volume:
0.89
Market Cap:
$253.99M
Revenue:
$128.45M
Net Income/Loss:
$6.54M
P/E Ratio:
136.20
EPS:
0.05
Net Cash Flow:
$-8.79M
1W Performance:
-0.73%
1M Performance:
-1.23%
6M Performance:
-8.84%
1Y Performance:
+32.23%
1-Day Range:
$6.74
$6.925
1-Week Range:
$6.64
$6.965
52-Week Range:
$3.6793
$7.99
Lifecore Biomedical Inc Stock (LFCR) Company Profile
Name
Lifecore Biomedical Inc
Sector
Phone
(952) 368-4300
Address
3515 LYMAN BOULEVARD, CHASKA
Compare LFCR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LFCR
Lifecore Biomedical Inc
|
6.81 | 253.99M | 128.45M | 6.54M | -8.79M | 0.05 |
|
RGC
Regencell Bioscience Holdings Ltd
|
78.00 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
161.67 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.50 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.89 | 47.60B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.89 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Lifecore Biomedical Inc Stock (LFCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-21-25 | Initiated | William Blair | Outperform |
| Sep-05-24 | Initiated | Craig Hallum | Buy |
| Aug-28-24 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Mar-20-23 | Downgrade | Stephens | Overweight → Equal-Weight |
Lifecore Biomedical Inc Stock (LFCR) Latest News
Lifecore Biomedical: Inflecting Financials Over Next 3 Years (NASDAQ:LFCR) - Seeking Alpha
Lifecore Signs 10-Year Manufacturing Deal To Support Novel Ophthalmic Therapy - Nasdaq
Lifecore Biomedical Q3 2025 slides: Revenue dip amid ambitious growth strategy By Investing.com - Investing.com South Africa
Lifecore signs 10-year manufacturing deal with key ophthalmic client By Investing.com - Investing.com Nigeria
Lifecore Biomedical Q3 2025 slides: Revenue dip amid ambitious growth strategy - Investing.com Nigeria
Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Stockholders to Connect - ACCESS Newswire
Lifecore Biomedical Enters 10-Year Commercial Manufacturing & Supply Agreement with Existing Customer - Contract Pharma
2025-06-17 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Stockholders to Connect | NDAQ:LFCR | Press Release - Stockhouse
Lifecore signs 10-year manufacturing deal with key ophthalmic client - Investing.com
Lifecore (LFCR) Secures Decade-Long Manufacturing Deal for Ophth - GuruFocus
Lifecore Biomedical Signs 10-Year Manufacturing, Supply Deal With Ophthalmic Therapy Customer - marketscreener.com
Lifecore (LFCR) Secures Decade-Long Manufacturing Deal for Ophthalmic Therapy | LFCR Stock News - GuruFocus
Lifecore Biomedical Signs 10-Year Commercial Manufacturing Agreement to Advance Novel Ophthalmic Therapeutic - Nasdaq
Lifecore Biomedical Signs New 10-Year Commercial Manufacturing and Supply Agreement with Key Existing Customer - GlobeNewswire
Lifecore Biomedical Lands Multi-Million Dollar, 10-Year Manufacturing Contract for Novel Eye Treatment - Stock Titan
Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Lifecore Biomedical, Inc. (NASDAQ:LFCR) Shares Purchased by Bank of America Corp DE - Defense World
Lifecore Biomedical receives accelerated payment of remaining $10M in proceeds from equipment sale - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Lifecore receives early $10 million payment for equipment sale By Investing.com - Investing.com South Africa
Lifecore Biomedical Receives Accelerated Payment of Remaining $10 Million in Proceeds from Prior Equipment Sale - GlobeNewswire
Lifecore Receives Full Payment Early For $17 Mln Equipment Sale - Nasdaq
Lifecore Biomedical Receives Remaining $10 Million for Sale of Isolator Filler Ahead of Schedule - marketscreener.com
Lifecore (LFCR) Completes $10 Million Equipment Sale Payment | LFCR Stock News - GuruFocus
Lifecore receives early $10 million payment for equipment sale - Investing.com Australia
Lifecore Biomedical Fast-Tracks $10M Equipment Payment as New Filler Promises $300M Revenue Potential - Stock Titan
2025-06-10 | Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Investors to Inquire about Securities Investigation | NDAQ:LFCR | Press Release - Stockhouse
Squarepoint Ops LLC Reduces Position in Lifecore Biomedical, Inc. (NASDAQ:LFCR) - Defense World
(LFCR) Long Term Investment Analysis - news.stocktradersdaily.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lifecore Biomedical, Inc. (LFCR) And Encourages Shareholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Deutsche Bank AG Reduces Position in Lifecore Biomedical, Inc. (NASDAQ:LFCR) - Defense World
Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Contrasting Lifecore Biomedical (NASDAQ:LFCR) & Liquidia (NASDAQ:LQDA) - Defense World
Lifecore Biomedical, Inc. (NASDAQ:LFCR) Shares Sold by BNP Paribas Financial Markets - Defense World
Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Lifecore Biomedical (NASDAQ:LFCR) shareholders have endured a 37% loss from investing in the stock five years ago - Yahoo Finance
How the (LFCR) price action is used to our Advantage - news.stocktradersdaily.com
Lifecore appoints new chief commercial officer to drive growth By Investing.com - Investing.com South Africa
Lifecore Biomedical Appoints CCO - Contract Pharma
Lifecore Biomedical Names Mark Dafonseca Chief Commercial Officer - marketscreener.com
LFCR Appoints New Chief Commercial Officer | LFCR Stock News - GuruFocus
Lifecore appoints new chief commercial officer to drive growth - Investing.com
Lifecore Biomedical Names Mark DaFonseca Chief Commercial Officer - GlobeNewswire
Lifecore Biomedical Taps 30-Year Pharma Veteran as CCO to Accelerate CDMO Market Expansion - Stock Titan
Northern Trust Corp Purchases 28,019 Shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR) - Defense World
Analysts Set Expectations for LFCR Q4 Earnings - Defense World
William Blair Begins Coverage on Lifecore Biomedical (NASDAQ:LFCR) - Defense World
What Makes Lifecore Biomedical (LFCR) a Beneficiary of the Trade Policies? - Insider Monkey
Lifecore Biomedical (LFCR) Receives 'Outperform' Rating from Wil - GuruFocus
Lifecore stock gains on Outperform rating by William Blair - Investing.com Canada
Lifecore Biomedical Inc Stock (LFCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):